Abrocitinib, a once-daily Janus kinase (JAK) 1 selective inhibitor, succeeded as a treatment for moderate-to-severe atopic dermatitis, in accordance to the segment III JADE MONO-2…
Abrocitinib, a once-daily Janus kinase (JAK) 1 selective inhibitor, succeeded as a treatment for moderate-to-severe atopic dermatitis, in accordance to the segment III JADE MONO-2…